Candel Therapeutics raises $92M in public offering following prostate cancer trial success
Portfolio Pulse from
Candel Therapeutics Inc (NASDAQ:CADL) successfully raised $92 million through a public offering after positive results from a prostate cancer trial. The offering included 12 million shares at $6 each and pre-funded warrants for 3.3 million shares.
December 16, 2024 | 9:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Candel Therapeutics raised $92 million in a public offering following successful prostate cancer trial results. This capital boost could support further research and development, potentially increasing investor confidence.
The successful capital raise of $92 million following positive trial results is likely to boost investor confidence and support further R&D, which could positively impact CADL's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100